Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Investing

ORI HEALTHCARE FUND INVESTS IN PILLAR BIOSCIENCES

Published by Gbaf News

Posted on May 13, 2016

Featured image for article about Investing

ORI Healthcare Fund L.P. (ORI Fund) announces the completion of US$18 million investment into Pillar Biosciences Inc., a Boston-based start-up specialized in next generation sequencing (“NGS”)-based clinical oncology testing in order to bring affordable precision medicine to cancer patients globally.

ori Pillar Biosciences is prized with its patent-pending targeted sequencing technology platform and a proprietary data analysis toolkit, which achieve high sensitivity and specificity with clinical samples. The platform provides a fast, simple and affordable targeted sequencing method for NGS-based oncology testing. The start-up has also released its beta version of Lung & Colon Cancer Somatic Mutation Panel and BRCA1 & BRCA2 Germline Mutation Panel to cancer centers and clinical testing companies in US and China for validation studies.

The investment from ORI Fund will help the company continue its R&D efforts in tumor tissue genotyping area, i.e. integration of back-end information analytics capability, as well as adding liquid biopsy products for cancer therapeutic decision-making and treatment monitoring.

ORI Capital, the manager of ORI Fund, believes that NGS-based oncology testing is an integral component of precision cancer therapeutics and it helps to make steady advances in the molecular diagnosis of cancers. In particular, NGS makes it possible to detect cancer in early stages by directly measuring circulating tumor DNA.

The transaction is consistent with ORI Fund’s investment focus in the clinical oncology space. “We are excited to partner with Pillar Biosciences to further advance the modern cancer treatment, which is the main focus of our fund,” commented Ms. Simone Song, Senior Partner of ORI Fund. “We hope the partnership between us will help speed up the development of affordable precision treatments for cancer patients worldwide.”